CytomX Therapeutics, Inc. (CTMX)
2.56
-0.02
(-0.78%)
USD |
NASDAQ |
Oct 06, 16:00
2.57
+0.01
(+0.39%)
Pre-Market: 09:15
CytomX Therapeutics Gross Profit Margin (Quarterly) : 96.69% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 96.69% |
| March 31, 2026 | 97.55% |
| December 31, 2025 | 23.08% |
| September 30, 2025 | 97.75% |
| June 30, 2025 | 98.14% |
| March 31, 2025 | 99.24% |
| December 31, 2024 | 98.92% |
| September 30, 2024 | 98.72% |
| June 30, 2024 | 98.17% |
| March 31, 2024 | 98.87% |
| December 31, 2023 | 98.17% |
| September 30, 2023 | 94.60% |
| June 30, 2023 | 93.80% |
| March 31, 2023 | 93.63% |
| December 31, 2022 | 92.60% |
| September 30, 2022 | 86.68% |
| June 30, 2022 | 92.00% |
| March 31, 2022 | 84.20% |
| December 31, 2021 | 92.48% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 97.79% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 83.68% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -42.00% |
| Return on Assets | -32.47% |
| Return on Invested Capital | -40.91% |
| Profit Margin (Quarterly) | -1.46K% |
| Operating Margin (Quarterly) | -1.68K% |
| Return on Net Operating Assets | -503.0% |